Denali Therapeutics Inc <DNLI.O>: JPMorgan resumes coverage with overweight rating; target price $29
DNLI•Related News
Granite Construction appoints George L. Nash Jr. to board of directors
GVA•
Velocity Financial, Inc. <VEL.N>: Wells Fargo Cuts Target Price to $19 From $20
VEL•
KE Holdings files HKEX next-day disclosure return reporting share repurchase for cancellation
BEKE•
Six Flags Entertainment Corp <FUN.N>: Mizuho cuts to underperform from outperform; cuts target price to $10 from $28
FUN•
Fidelity National Financial <FNF.N>: Barclays raises target price to $54 from $51
FNF•